DoH Policies screened during the period: 1 April 2017 – 30 June 2017
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- Amendment of General Dental Services Regulations (NI) 1993 (“the GDS Regulations”)
- NICE Public Health Guideline NG58 - Coexisting severe mental illness and substance misuse: community health and social care services
- NICE Public Health Guideline NG60 - HIV testing: increasing uptake among people who may have undiagnosed HIV
- NICE Public Health Guideline NG64 - Drug misuse prevention: targeted interventions
- NICE Clinical Guideline NG65 - Spondyloarthritis in over 16s: diagnosis and management
- NICE Clinical Guideline NG66 - Mental health of adults in contact with the criminal justice system
- NICE Public Health Guideline NG68 - Sexually transmitted infections: condom distribution schemes
- NICE Public Health Guideline PH51 - Contraceptive services for under 25s
- NICE Technology Appraisal TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (review of TA176 & part review of TA240)
- NICE Technology Appraisal TA440 - Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine
- NICE Technology Appraisal TA441 - Daclizumab for treating relapsing-remitting multiple sclerosis
- NICE Technology Appraisal TA442 - Ixekizumab for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA443 - Obeticholic acid for treating primary biliary cholangitis
- NICE Technology Appraisal TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs